In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...
DENVER — Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions in immunocompromised patients, according to results of a phase 3 ...
Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...
Future Microbiol. 2010;5(1):15-22. The ocular and genital mucosa are key players in regulation of herpes simplex virus (HSV) susceptibility and recurrent disease. Prophylactic and therapeutic ...
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. In the ...
A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
The MarketWatch News Department was not involved in the creation of this content. BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical ...
Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, ...
Hosted on MSN
Anal Herpes: Symptoms, Diagnosis, and Treatment
Anal herpes is caused by the herpes simplex virus (HSV) and is usually transmitted by anal sex but, in some cases, can also be transmitted through oral sex. During an outbreak, painful blisters appear ...
MEXICO CITY (Reuters Health) - Long-term treatment of genital herpes with the drug acyclovir does not reduce the rate of new HIV infections, researchers reported at the International AIDS Conference ...
BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results